Evidence map›Paper›PMID 11308268›Full record

ReviewBritish journal of cancer2001

Development and characterization of novel erythropoiesis stimulating protein (NESP).

J C Egrie, J K Browne

2 registry-linked trialsOpen access · hybridAbstract readComparative StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 103 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 6 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00381836 phase2 / phase3terminatednot on this mapstarted 2006, after this paper: background citation

A Randomized, Multi-center Study to Assess the Effect of Darbepoetin Alfa (Aranesp®) for the Treatment of Anemia in Patients With Advanced Hormone Independent Prostate Cancer and Anaemia

TypeinterventionalSponsorUniversity of AarhusRan2006 to 2007Enrolled140ConditionsProstatic Neoplasms, AnemiaArmsDarbepoetin Alfa
NCT01039350 phase2terminatednot on this mapstarted 2006, after this paper: background citation

Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.

TypeinterventionalSponsorFundacion para el Estudio de la Hematologia y Hemoterapia en AragonRan2006 to 2009Enrolled80ConditionsMyelodysplastic SyndromeArmsDarbepoetin alfa
3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 6 syntheses or guidelines pooled it, 511 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Intravenous administration of darbepoetin to NICU patients.Journal of perinatology : official journal of the California Perinatal Association · 2006
    Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Unveiling the Accurate Site-SpecificAnalytical chemistry · 2025
    Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

J C EgrieAmgen Inc, One Amgen Center Drive, MS 27-4-A, Thousand Oaks, CA 91320-1799, USA.
J K Browne
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Studies on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of the molecule and its serum half-life and in vivo biological activity, but an inverse relationship with its receptor-binding affinity. These observations led to the hypothesis that increasing the carbohydrate content, beyond that found naturally, would lead to a molecule with enhanced biological activity. Hyperglycosylated recombinant human EPO (rHuEPO) analogues were developed to test this hypothesis. Darbepoetin alfa (novel erythropoiesis stimulating protein, NESP, ARANESP, Amgen Inc, Thousand Oaks, CA), which was engineered to contain 5 N-linked carbohydrate chains (two more than rHuEPO), has been evaluated in preclinical animal studies. Due to its increased sialic acid-containing carbohydrate content, NESP is biochemically distinct from rHuEPO, having an increased molecular weight and greater negative charge. Compared with rHuEPO, it has an approximate 3-fold longer serum half-life, greater in vivo potency, and can be administered less frequently to obtain the same biological response. NESP is currently being evaluated in human clinical trials for treatment of anaemia and reduction in its incidence.

Indexed as

AnimalsCarbohydrate ConformationCross-Over StudiesDarbepoetin alfaDrug Administration ScheduleDrug DesignDrug Evaluation, PreclinicalErythropoiesisErythropoietinGlycosylationHalf-LifeHematocritHumansMiceN-Acetylneuraminic AcidPeritoneal DialysisDarbepoetin alfaErythropoietinN-Acetylneuraminic AcidRecombinant Proteins

Identifiers

PMID11308268
PMCPMC2363897
OpenAlexW2145908121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.